Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Sees Large Increase in Short Interest

Posted by Donna Armstrong on Apr 26th, 2026

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,024 shares, an increase of 93.9% from the March 31st total of 528 shares. Based on an average daily volume of 1,245 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.6% of the company’s stock are sold short.

Amplify Weight Loss Drug & Treatment ETF Stock Up 0.3%

NYSEARCA THNR traded up $0.07 during trading hours on Friday, hitting $24.48. 825 shares of the company were exchanged, compared to its average volume of 2,202. The company has a 50 day moving average of $24.90 and a two-hundred day moving average of $25.05. Amplify Weight Loss Drug & Treatment ETF has a 52-week low of $20.98 and a 52-week high of $27.28. The firm has a market cap of $4.16 million, a price-to-earnings ratio of 24.31 and a beta of 0.58.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC boosted its stake in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) by 5.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned approximately 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Company Profile

(Get Free Report)

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.